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GLI-similar 1 (GLIS1) is important for the reprogramming of ﬁbroblasts into induced pluripotent stem
cells (iPSCs). However, the molecular mechanisms of regulation of GLIS1 expression remain unclear.
We have therefore examined GLIS1 expression in various cancer cell lines and demonstrated that GLIS1
expression was dramatically increased under hypoxic conditions. Importantly, GLIS1 expression was sig-
niﬁcantly attenuated in VHL-overexpressing renal cell carcinoma cells compared to the VHL-deﬁcient
parent control. Moreover, promoter analysis demonstrated that GLIS1 transcription was regulated by
hypoxia through a hypoxia-inducible factors (HIFs)-dependent mechanism. Co-transfection experiments
revealed that HIF-2a had greater potency on the GLIS1 promoter activation than HIF-1a. Subsequent
studies using wild-type and mutant HIF-2a demonstrated that DNA binding activity was not necessary
but TADs were critical for GLIS1 induction. Finally, co-transfection experiments indicated that HIF-2a
cooperated with AP-1 family members in upregulating GLIS1 transcription. These results suggest that
the hypoxic signaling pathway may play a pivotal role in regulating the reprogramming factor GLIS1,
via non-canonical mechanisms involving partner transcription factor rather than by direct HIF
transactivation.
 2013 Elsevier Inc. All rights reserved.1. Introduction
The Krüppel-like protein Gli-similar 1 (GLIS1) was reported to
be both temporally and spatially regulated, suggesting that it
may play a role in the regulation of embryonic developmental pro-
grams at speciﬁc stages [1,2]. GLIS1 expression was increased by
phorbol-12-myristate-13-acetate (PMA) or interferon c treatment
and stable transfection of GLIS1DC that lacks activation domains
prompted PMA-induced epidermal differentiation. This indicated
a regulatory role for GLIS1 in aberrant epidermal differentiation
and remodeling of tumorigenic PMA-treated psoriatic skin [3]. Cru-
cially, GLIS1 markedly enhances the generation of induced plurip-
otent stem cells (iPSCs) from both mouse and human ﬁbroblasts
when it is expressed together with OCT3/4 (POU5F1), SOX2 and
KLF4. GLIS1 is able to replace oncogenicMYC, resulting in decreasedtumorigenicity as well as improving safety and efﬁciency of iPS cell
production, demonstrating its utility in stem cell biology [4].
Stem cells frequently reside in a specialized physiological
microenvironment called the stem cell niche. The role of the niche
is to maintain stem cell properties such as pluripotency and self-
renewal. Recent evidence suggests that hypoxia may be an impor-
tant physiological component of the microenvironment necessary
for stem cell maintenance [5,6]. Consistent with this, hypoxic
(low oxygen) conditions were able to improve the efﬁciency of
iPS cell generation from mouse and human somatic cells [7]. In-
deed, the master regulator of stemness Oct-4 is a direct transcrip-
tional target of hypoxia-inducible factor-2-alpha (HIF-2a also
known as endothelial PAS domain protein 1 or EPAS1) which is
one of the main transcription factors of the hypoxia pathway
further highlighting the importance of hypoxia in stem cells
biology [8]. Mechanistically, hypoxia-inducible factor alpha
(HIF-a) subunits are degraded through von Hippel–Lindau (VHL)-
mediated ubiquitin–proteasomal degradation under normoxic
conditions, and hypoxia stabilizes HIF-a thereby allowing their
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to hypoxia response elements (HRE), resulting in the activation of
multiple genes [9].
Therefore, given the importance of GLIS1, hypoxia and HIFs in
stem cell biology, we examined the potential role of hypoxia in
transcriptional regulation of GLIS1, and provide novel insights into
the molecular mechanisms governing GLIS1 expression under hyp-
oxic conditions.2. Materials and methods
2.1. Cell culture and RNA preparation
Human breast cancer (MCF-7, BT-474, MDA-MB-231, SKBR-3,
and ZR-75-1), lung cancer (A549), liver cancer (HepG2), oral cancer
(Ca9-22, KOSC-2, HSC-2, HSC-3 and HSC-4), renal cancer (RCC4/
VHL, RCC4/pcDNA) and mouse liver cancer cell lines (Hepa1c4)
were maintained in RPMI1640 or Dulbecco’s modiﬁed Eagle’s min-
imal essential medium (DMEM) (NACALAI TESQUE, Inc., Kyoto, Ja-
pan) containing 10% fetal bovine serum (FBS; BioWhittaker,
Verviers, Belgium) as previously described [10–12]. For expression
analysis, cells (0.5–1.0  106/10 cm diameter dish) were cultured
under normoxic (21% pO2) or hypoxic (1% pO2) conditions for 6,
12, 24, or 48 h in a hypoxia chamber. Cells were then harvested
and stored at 80 C until use. Total RNA was extracted from fro-
zen cell pellets using the NucleoSpin RNA II kit (MACHEREY–NA-
GEL, Düren, Germany) according to manufacturer instructions.
2.2. Real-time reverse transcription-polymerase chain reaction (RT-
PCR) analysis
Two micrograms of total RNA extracted from each cell line were
reverse transcribed using the High-Capacity cDNA Archive™ Kit
(Applied Biosystems, Foster City, CA, USA). A 1/200 dilution of
the cDNA was subjected to real-time RT-PCR using primers (ﬁnal
concentration of 200 nM each) and MGB probe (ﬁnal concentration
of 100 nM, the Universal Probe Library: UPL, Roche Diagnostics, To-
kyo, Japan) (shown in Supplementary Table) sets with Pre-Devel-
oped TaqMan™ Assay Reagents (Applied Biosystems) for
quantitation of GLIS1, HIF1A, and EPAS1 expression with ACTB as
an internal housekeeping control. PCR reactions were carried out
using 7500 Real-Time PCR System (Applied Biosystems) under
the following standard conditions. Three independent measure-
ments were averaged and relative gene expression levels were cal-
culated as a ratio against ACTB expression for each cell line.
2.3. Immunoblot analysis
To analyze GLIS1, HIF-1a, or HIF-2a protein expression, whole
cell extracts were prepared from cultured cells with or without
hypoxic treatment as previously described [12,13]. Anti-GLIS1
(Epitomics, Burlingame, CA, USA), anti-HIF-1as (BD Pharmingen,
San Diego, CA, USA), anti-HIF-2a (Cell Signaling Technology, Inc.,
Danvers, MA, USA), or anti-b-actin (Sigma, St. Louis, MO, USA) were
used as primary antibodies, and anti-mouse Ig or anti-rabbit Ig
horseradish peroxidase conjugate (Amersham Life Science, Buck-
inghamshire, UK) in Can Get Signal solution 2 were used as sec-
ondary antibodies. Immunocomplexes were visualized using the
enhanced chemiluminescence reagent ECL Plus (NEN Life Science
Products, Inc., Boston, MA, USA).
2.4. Plasmid constructs
A 1.62 kb DNA fragment including the 50 untranslated region of
the GLIS1 gene (1556 to +66 from the transcriptional start site at+1; GenBank: NT_032977) was ampliﬁed by PCR fromMCF-7 geno-
mic DNA and subcloned into the XhoI and BglII sites of the lucifer-
ase reporter plasmid pGL4.26 (Promega, Madison, WI, USA) and
designated pGL4.26-GLIS1 Pro1556. Several 50 deletion mutants
of pGL4.26-GLIS1 Pro1556 were constructed by PCR cloning within
the regions 732 to +66 (pGL4.26-GLIS1 Pro732) and 228 to +66
(pGL4.26-GLIS1 Pro228). Base change mutants of putative hypoxia
response elements (HRE) or AP-1 binding sites, were generated by
PCR site-directed mutagenesis as previously reported [12,13]. The
HRE-luciferase reporter was constructed by subcloning of annealed
HRE consensus oligos into the NheI and XhoI sites of pGL4.26
(pGL4.26-5xHRE). Full-length HIF-1a, HIF-2a mutants of HIF-2a
72–870 or HIF-2a 2–332 or MYC cDNA was ampliﬁed by PCR from
HSC2 cDNA and subcloned into p3xFLAG-CMV™-10 (Sigma) or
pcDNA™3.1/V5-His (Invitrogen, Carlsbad, CA, USA) expression
vectors. All constructs were conﬁrmed by sequence analysis. ARNT
(pCMV-ARNT) and IPAS (pCMV-FLAG-IPAS) expression vectors are
as previously described [14]. Rat Jun/human b-actin and human
FOS expression vectors were generously provided by Dr. Masaharu
Sakai (Hokkaido University) [15].
2.5. Luciferase reporter assays
Transient transfections were performed with combinations of
reporter constructs (0.2 lg/15 mmwell) and expression vectors
(0.1–0.4 lg/15 mmwell) mixed with 0.9 ll of TransIT-LT1 Trans-
fection Reagent (TaKaRa Bio, Inc., Shiga, Japan). The Renilla lucifer-
ase vector (pRL-SV40, 1.0 ng/15 mmwell, Promega) was used as a
transfection efﬁciency control. Cells were incubated for 24 h after
transfection prior to analysis of luciferase reporter activity. Lucifer-
ase luminescence was measured using a single-sample lumino-
meter, the Biolumat LB 9505 (BERTHOLD TECHNOLOGIES GmbH
& Co. KG, BadWildbad, Germany) with the Dual-Luciferase Repor-
ter Assay System (Promega). Promoter activity was calculated as
the ratio of ﬁreﬂy to Renilla luciferase readings, and the average
of at least three independent experiments was taken.
2.6. Statistical analysis
All statistical tests were performed using the StatView version
5.0 software (SAS Institute Inc., NC, USA) and Microsoft Excel
2008 for Mac version 12.3.6. Student’s t-test was used to determine
P-values with ⁄ indicating P < 0.05, ⁄⁄P < 0.01 and ⁄⁄⁄P < 0.001.3. Results
3.1. Hypoxia induces GLIS1 expression in cancer cells in a VHL- and
HIF-dependent manner
To determine how GLIS1 was transcriptionally regulated, we
ﬁrst examined expression levels of GLIS1 in cancer cell lines of di-
verse origins, including head and neck, breast, lung, liver and renal
cancers under hypoxic compared to normoxic conditions. Real-
time RT-PCR analysis revealed that baseline expression levels of
GLIS1 were variable among cell lines with MCF-7 breast and
RCC4 renal cancer cells showing the highest expression. Notably,
GLIS1 expression was signiﬁcantly increased under hypoxic condi-
tions in 6 cell lines (breast cancer MCF-7, BT-474, lung cancer
A549, liver cancer HepG2, oral cancer Ca9-22 and renal cancer
RCC4, Fig. 1A–E) suggesting that this was a common response to
hypoxia. Importantly, GLIS1 expression was signiﬁcantly attenu-
ated in RCC4 cells transfected with VHL expression vector (RCC4/
VHL) compared to the original VHL-deﬁcient RCC4 parental cell
line that constitutively expresses the HIFs. This suggested a role
for the VHL-mediated degradation of HIFs on GLIS1 regulation,
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Fig. 1. GLIS1 is expressed in diverse cancer cell lines under normoxic and hypoxic conditions. Expression levels of GLIS1 in various cancer cell lines of different tissue origins,
including (A) breast, (B) lung, (C) liver, (D) oral, and (E) renal cancers, were quantiﬁed by real-time RT-PCR following normoxia or hypoxia treatments for 24 h. Time-course
kinetics of GLIS1 expression were obtained after hypoxia treatment of MCF-7 cells for the indicated durations followed by analysis using real-time RT-PCR (F) or
immunoblotting (G). Relative GLIS1 expression levels were calculated after normalization against housekeeping ACTB expression. Each bar represents the mean + SD for at
least three independent experiments. Statistical signiﬁcance was calculated between normoxic and hypoxic samples, or for the indicated paired samples with ⁄P < 0.05,
⁄⁄P < 0.01 and ⁄⁄⁄P < 0.001.
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against HIF1A (siHIF1A) and EPAS1/HIF2A (siEPAS1) (Supplemen-
tary Fig. 2). Time-course kinetics of GLIS1 expression showed that
the gene was induced beginning after 12 h incubation under hyp-
oxic conditions, and continued to increase robustly up to the
48 h time point in our experiments (Fig. 1F). Furthermore, immu-
noblot analysis showed increased expression of the GLIS1 protein
under hypoxic conditions consistent with the RT-PCR analysis
(Fig. 1G). Interestingly while HIF-1a protein levels were transiently
and signiﬁcantly accumulated after 24 h hypoxia, HIF-2a protein
remained weakly expressed in MCF-7 cells.3.2. Hypoxia regulates GLIS1 promoter activity via HIF-signaling but
not through the HRE consensus
To clarify the mechanisms by which HIFs mediate the induction
of GLIS1, we next subcloned the 50 ﬂanking region of exon 1 and
promoter region of GLIS1 (1556 to +66 with the transcriptional
start site at +1) containing two HRE consensus sequences into
the luciferase reporter vector pGL4.26 (pGL4.26-GLIS1 Pro1556)
(Fig. 2A and C, and Supplementary Fig. 1). Transient transfection
experiments and luciferase assays indicated that the cloned GLIS1
50 fragment had strong promoter activity under normoxic condi-
tions in both MCF-7 and MDA-MB-231 cells compared to the
empty control reporter pGL4.26 (Fig. 2B and C). Furthermore, pro-
moter activity was signiﬁcantly increased under hypoxic condi-
tions in both cell lines. To identify the GLIS1 promoter elements0 
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ity. Taken together, these results show that the hypoxia responsive
region of the GLIS1 promoter is contained within the shortest frag-
ment from 228 to +66 of GLIS1 (Fig. 2D). Since there were no con-
sensus HRE sequences found in this short fragment, we focused on
the similar GTG-motifs that are adjacent to the transcriptional start
site (Fig. 2E, and Supplementary Fig. 1). Point mutations in the dif-
ferent GTG-motifs (mt3 or mt4) to GAG resulted in signiﬁcant
reduction of GLIS1 promoter activity but did not affect hypoxic
induction (Fig. 2E). Interestingly, point mutation in the most 50
GTG-motifs (mt5) abolished basal activity of the GLIS1 promoter
and also hypoxic inductions. Therefore this site may correspond
to an important regulatory element necessary for the expression
of GLIS1.3.3. HIF-2a predominantly regulates GLIS1 promoter activity via its C-
terminal domain
To determine the functional domains of HIF that drive GLIS1
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were performed in MCF-7 cells. Notably, FLAG-tagged HIF-2a dra-
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HIF-2a speciﬁc protein domains that were responsible for
transcriptional activation. We performed further co-transfection
experiments with mutated HIF-2a (Fig. 3C). Surprisingly, a mutant
HIF-2a lacking the basic-helix-loop-helix (bHLH) DNA binding do-
main could activate GLIS1 promoter, although this mutant protein
was not able to bind DNA (Fig. 3D). On the other hand, a mutant
HIF-2a lacking the C-terminal transactivation domains (TADs)
failed to activate the promoter. Furthermore, coexpression of the
inhibitory PAS domain protein (IPAS) interfered with HIF-2a-
activated GLIS1 promoter activity, suggesting a possible role for
protein–protein interaction that may include dimerization with
ARNT, a classical transcriptional co-partner of HIFs (Fig. 3E).
However, co-transfection experiments using the Arnt-deﬁcient
hepatoma mouse cell line Hepa1c4 suggested that Arnt was inad-
equate for the activation of the GLIS1 promoter (Supplementary
Fig. 3). Therefore, HIF-2a transactivation of the GLIS1 promotermay not depend on ARNT but require interaction with alternative
transcriptional partners.
3.4. HIF-2a cooperates with AP-1 transcription factor family members
to drive GLIS1 expression
To determine what alternative factors and regulatory mecha-
nisms may be acting upon the GLIS1 promoter, we interrogated
transcription factor chromatin immunoprecipitation-sequencing
(ChIP-Seq) datasets from the ENCODE consortium to identify can-
didate transcription factor binding within the immediate 50 pro-
moter region of GLIS1. As a result, we found evidence for the
binding of AP-1 family members in diverse cell types within the
vicinity of the GLIS1 transcription start site (Supplementary
Fig. 4). Based on these results we evaluated the effects of AP-1
family members, Jun and FOS as well as the proto-oncogene MYC
on the E-box motif GTG on GLIS1 promoter activities in MCF-7 cells.
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Fig. 3. HIF-2a predominantly regulates GLIS1 promoter activity by non-canonical mechanisms. Increasing amounts of FLAG-tagged HIF-1a or HIF-2a expression vectors were
co-transfected with the pGL4.26-GLIS1 Pro228 promoter luciferase construct (A) or HRE-driven luciferase reporter (B) in MCF-7 cells, and incubated under normoxic
conditions for 24 h. Schematic representation of FLAG-tagged full-length (2–870 residues) and deletion mutants (72–870 or 2–332 residues) of HIF-2a are shown (C). The
various FLAG-tagged HIF-2a expression vectors (D) or full-length HIF-2a with or without IPAS (E) were co-transfected with the minimal pGL4.26-GLIS1 Pro228 promoter
luciferase reporter in MCF-7 cells, and incubated under normoxic conditions for 24 h. Relative ﬁreﬂy luciferase activity was calculated as above. Each bar represents
mean + SD for at least three independent experiments. Statistical signiﬁcance was calculated for all test conditions over the empty vector control (FLAG) and between HIF-1a,
HIF-2a or others with ⁄P < 0.05 and ⁄⁄⁄P < 0.001.
504 E. Khalesi et al. / Biochemical and Biophysical Research Communications 441 (2013) 499–506Transient transfection experiments showed that overexpression of
Jun, FOS, or MYC alone could transactivate the promoter where Jun
showed the strongest effect (Fig. 4). Interestingly, co-transfection
of HIF-2a with Jun or FOS, but not MYC, synergistically increased
GLIS1 promoter activity, suggesting cooperation among these
factors.4. Discussion
A novel Krüppel-like protein Gli-similar 1 (GLIS1) was recently
shown to be a reprogramming factor that can be used to replace
MYC during the production of iPSCs together with POU5F1, SOX2
and KLF4, although the molecular mechanisms governing GLIS1
R
el
at
iv
e 
lu
ci
fe
ra
se
 a
ct
iv
ity
GLIS1 Pro228pGL4
HIF-2
FLAG FLAG
FLAG Jun FOS FOS MYC
FLAG
0 
50 
100 
150 
200 
250 
FLAG
FLAG
Jun
MYC
*** *
**
***
***
***
*** **
***
**
***
*****300 
Fig. 4. HIF-2a regulates GLIS1 promoter activity by possible cooperation with AP-1 family members. The GLIS1 promoter luciferase reporter (pGL4.26-GLIS1 Pro228) was co-
transfected with or without the transcription factors HIF-2a, Jun, FOS, MYC or various permutations as indicated in MCF-7 cells, and incubated under normoxic conditions for
24 h. Relative ﬁreﬂy luciferase activities were calculated as above. Each bar represents mean + SD for at least three independent experiments. Statistical signiﬁcance was
calculated between empty vector control (FLAG) and HIF-2a overexpression samples, empty vector (FLAG) and other samples, or paired as indicated with ⁄P < 0.05, ⁄⁄P < 0.01
and ⁄⁄⁄P < 0.001.
E. Khalesi et al. / Biochemical and Biophysical Research Communications 441 (2013) 499–506 505function were not determined [3]. Here, we demonstrated for the
ﬁrst time that hypoxia, a prevalent and important microenviron-
ment condition for the maintenance of stemness, regulated
GLIS1 expression via novel mechanisms. Hypoxia-inducible factors,
especially HIF-2a, were found to cooperate with AP-1 family mem-
bers in upregulating GLIS1 transcription under hypoxic conditions.
When we evaluated expression levels of GLIS1 in diverse types
of cancer cell lines, we found that GLIS1 expression was variable
among cell lines with relatively high expression found in MCF-7
breast and RCC4 renal cancer cells, but with low levels in most of
other cells. Expression of GLIS1 in cancer cells has not been re-
ported so far, but the gene is known to be temporally and spatially
expressed in a dynamic manner during mouse embryonic develop-
ment that is consistent with the speciﬁcation of downstream cell
fates from stem and progenitor cells [1,2]. Because it might have
speciﬁc tissue and/or stage-dependent expression, further analyses
are obviously needed to understand the GLIS1 expression pattern
in human normal and cancer cells.
Interestingly, we found increased expression of GLIS1 under
hypoxic conditions in a number of cancer cell lines. Furthermore,
GLIS1 expression was signiﬁcantly lowered in RCC4 cells transfec-
ted with the VHL expression vector (RCC4/VHL) compared to the
VHL-deﬁcient parent. Parental RCC4 cells constitutively stabilize
HIFs even in normoxic conditions due to loss of VHL, but restora-
tion of VHL by transfection results in the rapid degradation of HIFs.
Taken together, these observations suggest a role for the VHL–HIF
mechanism on the regulation of GLIS1 expression. We indeed
found that suppression of HIFs attenuated hypoxic induction of
GLIS1, suggesting that hypoxia-driven HIFs transcriptionally upreg-
ulate GLIS1. The time-course experiments showing that GLIS1 be-
gins to increase under hypoxic conditions after 12 h incubation
or more, suggesting that the gene was subjected to more immedi-
ate transcriptional regulation rather than inhibition of mRNA deg-
radation further downstream.
We next subcloned the 50 region of GLIS1 into luciferase reporter
vectors and performed transient transfection experiments to
clarify the molecular mechanisms of transcriptional regulation by
hypoxia. Our results showed strong promoter activity of the clonedGLIS1 fragment under normoxic conditions, and this was
signiﬁcantly increased under hypoxia in both MCF-7 and MDA-
MB-231 cells, suggesting the presence of critical regulatory ele-
ments in the promoter region. We indeed found two consensus
HRE sequences on the GLIS1 promoter, but a series of transient
transfection experiments surprisingly indicated that the HRE
mutations did not affect basal promoter activity and hypoxic
inductions, suggesting adjacent promoter regions may instead be
responsible. Therefore, we searched for similar sequences to the
HREs namely the GTG-motifs that commonly allow binding of ba-
sic helix-loop-helix (bHLH)-Per/Arnt/Sim (PAS) family members
[16]. Strikingly, one of the GTG-motif mutants disrupted both GLIS1
basal activity and hypoxic response, suggesting that this site was
critical for transcriptional regulation under both normoxic (basal)
and hypoxic conditions. Interestingly, we noticed that this GTG-
motif overlaps with an AP-1 binding sequence. ENCODE data anal-
yses of ChIP-seq datasets revealed that there were binding of AP-1
family members in the region adjacent to the GLIS1 transcriptional
start site in different cell types. Our reporter experiments con-
ﬁrmed that the GLIS1 promoter was indeed activated during co-
transfection with the AP-1 family members, JUN or FOS. These re-
sults provide additional insights together with a previous report
showing that the mRNA levels of Glis1 were signiﬁcantly induced
in mouse skin upon treatment with PMA [2].
Moreover, deletion mutants of HIF-2a indicated that its DNA
binding domain may not be necessary to activate GLIS1 promoter,
but highlighted that it may cooperate with other proteins through
its C-terminal transactivation domains. Because the deletion of the
bHLH domain of HIF-2a abolishes canonical transcriptional activity
on HRE-reporters, our result suggests non-canonical mechanisms
at work on the GLIS1 promoter. It is known that the bHLH domain
of HIF-2a participates not only in DNA binding activity but it is also
important for dimerization with ARNT pointing towards a role for
the transcriptional co-partner in the mechanism [17]. In fact, co-
transfection experiments using the Arnt-deﬁcient hepatoma
mouse cell line Hepa1c4 suggested that Arnt might be necessary
but inadequate for the activation of the GLIS1 promoter (Supple-
mentary Fig. 3). This led to the search for alternative candidate
506 E. Khalesi et al. / Biochemical and Biophysical Research Communications 441 (2013) 499–506factors besides Arnt and demonstrated for the ﬁrst time that HIF-
2a may cooperate with AP-1 family members. Our co-transfection
experiments showed that JUN seemed to function in a more potent
manner than FOS on the GLIS1 promoter. While there have been
previous reports linking HIF-1a interaction with JUN, and cooper-
ativity with AP-1 binding sites under hypoxic conditions [18,19],
whether physical interaction between HIF-2a and JUN occurs re-
mains unclear but this could account for the functional cooperation
between the 2 transcription factors in GLIS1 regulation. It will be of
interest to elucidate the molecular mechanisms behind these novel
cooperative associations between HIF-2a and AP-1 given the
importance of both factors in cancer disease.
In conclusion, we demonstrated for the ﬁrst time that hypoxia-
regulated GLIS1 expression occurs via a novel mechanism requiring
the cooperation between HIFs, notably HIF-2a, and AP-1 family
members. This highlights possible roles for the interplay between
these factors in reprogramming, dedifferentiation and/or mainte-
nance of stemness in normal versus cancer cells.
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